Phospholipase C{beta}3 in mouse and human dorsal root ganglia and spinal cord is a possible target for treatment of neuropathic pain.

Proc Natl Acad Sci U S A

Department of Neuroscience, and Department of Clinical Science and Education, Section of Hand Surgery, Södersjukhuset, Karolinska Institutet, S 171 77 Stockholm, Sweden.

Published: December 2008

Treatment of neuropathic pain is a major clinical problem. This study shows expression of phospholipase ss3 (PLCss3) in mouse and human DRG neurons, mainly in small ones and mostly with a nonpeptidergic phenotype. After spared nerve injury, the pain threshold was strongly reduced, and systemic treatment of such animals with the unselective PLC inhibitor U73122 caused a rapid and long-lasting (48-h) increase in pain threshold. Thus, inhibition of PLC may provide a way to treat neuropathic pain.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2604939PMC
http://dx.doi.org/10.1073/pnas.0810899105DOI Listing

Publication Analysis

Top Keywords

neuropathic pain
12
mouse human
8
treatment neuropathic
8
pain threshold
8
pain
5
phospholipase c{beta}3
4
c{beta}3 mouse
4
human dorsal
4
dorsal root
4
root ganglia
4

Similar Publications

Neuropathic pain is a complex and debilitating condition resulting from nerve damage, characterized by sensations such as burning, tingling, and shooting pain. It is often associated with conditions such as multiple sclerosis (MS), Guillain-Barré syndrome (GBS), and diabetic polyneuropathy. Conventional pain therapies frequently provide limited relief and are accompanied by significant side effects, emphasizing the need to explore alternative treatment options.

View Article and Find Full Text PDF

Background: Morphine analgesic tolerance (MAT) limits the clinical application of morphine in the management of chronic pain. IIK7 is a melatonin type 2 (MT2) receptor agonist known to have antioxidant properties. Oxidative stress is recognized as a critical factor in MAT.

View Article and Find Full Text PDF

Emerging Psychotropic Drug for the Treatment of Trigeminal Pain: Salvinorin A.

Pharmaceuticals (Basel)

November 2024

Departamento de Farmacia, Facultad de Química, Universidad Nacional Autónoma de México, Ciudad Universitaria, Coyoacán, Ciudad de Mexico 04510, Mexico.

Trigeminal neuralgia (TN) is chronic pain caused by damage to the somatosensorial system on the trigeminal nerve or its branches, which involves peripheral and central dysfunction pain pathways. Trigeminal pain triggers disruptive pain in regions of the face, including within and around the mouth. Besides clinical experiences, translating the language of suffering into scientific terminology presents substantial challenges.

View Article and Find Full Text PDF

Discovery of Glucose Metabolism-Associated Genes in Neuropathic Pain: Insights from Bioinformatics.

Int J Mol Sci

December 2024

Department of Anesthesiology, Laboratory and Clinical Research Institute for Pain, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.

Metabolic dysfunction has been demonstrated to contribute to diabetic pain, pointing towards a potential correlation between glucose metabolism and pain. To investigate the relationship between altered glucose metabolism and neuropathic pain, we compared samples from healthy subjects with those from intervertebral disc degeneration (IVDD) patients, utilizing data from two public datasets. This led to the identification of 412 differentially expressed genes (DEG), of which 234 were upregulated and 178 were downregulated.

View Article and Find Full Text PDF

The Importance of Bright Spotty Lesions on Magnetic Resonance Imaging in Predicting Chronic Neuropathic Pain in Myelitis.

J Clin Med

December 2024

Department of Neurology, School of Medicine, Ajou University Medical Center, Ajou University, Suwon 16499, Republic of Korea.

: Chronic neuropathic pain (CNP) stands as one of the most debilitating complications in patients with myelitis owing to its challenging management. Bright spotty lesions (BSLs) are frequently observed in neuromyelitis optica spectrum disorder (NMOSD), but few reports have discussed CNP in myelitis. We aim to demonstrate that BSLs could be one of the potential prognostic factors for CNP development in myelitis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!